ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 17 No. 1 (2024), EXPERIMENTAL STUDIES
Vol. 17 No. 1 (2024)
EXPERIMENTAL STUDIES

The Therapeutic Effect of Antitumor Drugs Erufosine and Doxorubicin on the Metastatic Process in the Testes of Hamsters with Graffi Myeloid Tumor. Morphometric and Histological Studies

Published 17.05.2024
Iliana Najdenova Ilieva
Department of Experimental Morphology, Institute of Experimental Morphology, Pathology, and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
I.V. Sainova
Department of Experimental Morphology, Institute of Experimental Morphology, Pathology, and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
R.A. Toshkova
Department of Experimental Morphology, Institute of Experimental Morphology, Pathology, and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
A.K. Georgieva
Department of Experimental Morphology, Institute of Experimental Morphology, Pathology, and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
V.N. Nanev
Department of Experimental Morphology, Institute of Experimental Morphology, Pathology, and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
R.D. Tzoneva
Laboratories Transmembrane Signalling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria
2024-1
PDF_2024-17-1_18-26

Keywords

metastases
antitumor activity
erufosine
doxorubicin
Graffi myeloid tumor
morphology of testicular tissue
spermatogenesis
acute myeloid leukemia

How to Cite

Ilieva I.N., Sainova I.V., Toshkova R.A., Georgieva A.K., Nanev V.N., Tzoneva R.D. The Therapeutic Effect of Antitumor Drugs Erufosine and Doxorubicin on the Metastatic Process in the Testes of Hamsters with Graffi Myeloid Tumor. Morphometric and Histological Studies. Clinical Oncohematology. 2024;(1):18–26. doi:10.21320/2500-2139-2024-17-1-18-26.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Aim. The goal of the current study is directed to investigate the therapeutic effect of erufosine (ЕРС3) alone, as well as in combination with doxorubicin (DOX) on the development of metastases in the testes in an experimental model of transplantable Graffi myeloid tumor (GMT) in hamsters.

Materials & Methods. Experimental in vivo model of GMT in Golden Syrian hamsters was used. Animals were inoculated subcutaneously with live virus-transformed malignant cells. Testes from male tumor-bearing hamsters (TBHs), treated and non-treated with the antitumor agent erufosine alone or in combination with DOX, as well as untreated healthy controls, were subjected to morphometric and histological assays on the testicular architecture to evaluate potential antitumor/antimetastatic effects in in vivo conditions.

Results. The results showed no changes in blood vessels and morphology (impaired spermatogenesis and/or metastatic changes) of the testicular tissue in TBHs treated with antitumor agents (alone or in combination) compared to control healthy animals. In contrast, in the testes of TBHs without therapy, impaired spermatogenesis and foci of metastases, as well as significant changes in testicular blood vessels were found.

Conclusion. The data obtained demonstrated an antitumor/antimetastatic effect of EPC3 in the testes of hamsters in the experimental GMT model.

PDF_2024-17-1_18-26

References

  1. Benson JR, Jatoi I, Keisch M, et al. Early Breast Cancer. Lancet. 2009;373(9673):1463–79. doi: 10.1016/S0140-6736(09)60316-0.
  2. Kulbari A, Sheoravan A, Chaudhury A. Targeted Chemotherapeutics: An Overview of the Recent Progress in Effectual Cancer Treatment. Pharmacologia. 2013;4(9):535–52. doi: 10.17311/pharmacologia.2013.535.552.
  3. Gaudichon J, Jakobczyk H, Debaize L, et al. Mechanisms of Extramedullary Relapse in Acute Lymphoblastic Leukemia: Reconciling Biological Concepts and Clinical Issues. Blood Rev. 2019;36:40–56. doi: 10.1016/j.blre.2019.04.003.
  4. Unger C, Fleer EA, Kotting J, et al. Antitumoral Activity of Alkylphosphocholines and Analogues in Human Leukemia Cell Lines. Prog Exp Tumor Res. 1992;34:25–32. doi: 10.1159/000420829.
  5. Fiegl M, Lindner LH, Juergens M, et al. Erufosine, a Novel Alkylphosphocholine, in Acute Myeloid Leukemia: Single Activity and Combination with Other Antileukemic Drugs. Cancer Chemother Pharmacol. 2008;62(2):321–9. doi: 10.1007/s00280-007-0612-7.
  6. Jendrossek V, Hammersen K, Erdlenbruch B, et al. Structure-activity Relationships of Alkylphosphocholine Derivatives: Antineoplastic Action on Brain Tumor Cell Lines in vitro. Cancer Chemother Pharmacol. 2002;50(1):71–9. doi: 10.1007/s00280-002-0440-8.
  7. Vink SR, Schellens JHM, van Blitterwijk WJ, Verheij M. Tumor and Normal Tissue Pharmacokinetics of Perifosine, an Oral Anti-cancer Alkylphospholipid. Invest New Drug. 2005;23(4):279–86. doi: 10.1007/s10637-005-1436-0.
  8. Li Z, Tan F, Liewehr DJ, et al. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst. 2010;102(11):758–70. doi: 10.1093/jnci/djq125.
  9. Crul M, Rosing H, de Klerk GJ, et al. Phase I and Pharmacological Study of Daily Oral Administration of Perifosine (D-21266) in Patients with Advanced Solid Tumors. Eur J Cancer. 2002;38(12):1615–21. doi: 10.1016/S0959-8049(02)00127-2.
  10. Clive S, Gardiner J, Leonard RC. Miltefosine as a Topical Treatment for Cutaneous Metastases in Breast Carcinoma. Cancer Chemother Pharmacol. 1999;44(Suppl):S29–S30. doi: 10.1007/s002800051114.
  11. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood. 2001;98(13):3860–3. doi: 10.1182/blood.V98.13.3860.
  12. Rubel A, Handrick R, Lindner LH, et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol. 2006;1:1–17. doi: 10.1186/1748-717X-1-6.
  13. Rudner J, Ruiner C, Handrick R, et al. The Akt-inhibitor Erufosine Induces Apoptotic Cell Death in Prostate Cancer Cells and Increases the Short Term Effects of Ionizing Radiation. Radiat Oncol. 2010;5:108. doi: 10.1186/1748-717X-5-108.
  14. Jimenez-Lopez JM, Rios-Marco P, Marco C, et al. Alterations in the Homeostasis of Phospholipids and Cholesterol by Antitumor Alkylphospholipids. Lipids Health Dis. 2010;9:33. doi: 10.1186/1476-511X-9-33.
  15. Kaleagasıoglu F, Berger MR. Differential Effects of Erufosine on Proliferation, Wound Healing and Apoptosis in Colorectal Cancer Cell Lines. Oncol Rep. 2014;31(3):1407–16. doi: 10.3892/or.2013.2942.
  16. Van Blitterswijk WJ, Verheij M. Anticancer Mechanisms and Clinical Application of Alkylphospholipids. Biochim Biophys Acta. 2013;1831(3):663–74. doi: 10.1016/j.bbalip.2012.10.008.
  17. Bagley RG, Kurtzberg L, Rouleau C, et al. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemothe Pharmacol. 2011;68(6):1537–46. doi: 10.1007/s00280-011-1658-0.
  18. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin Pathways: Pharmacodynamics and Adverse Effects. Pharmacogenet Genomics. 2011;21(7):440–6. doi: 10.1097/FPC.0b013e32833ffb56.
  19. Heisig P. Type II Topoisomerases — Inhibitors, Repair Mechanisms and Mutations. Mutagenesis. 2009;24(6):465–9. doi: 10.1093/mutage/gep035.
  20. Greco WR, Faessel H, Levasseur L. The Search for Cytotoxic Synergy between Anticancer Agents: a Case of Dorothy and the Ruby Slippers? J Natl Cancer Inst. 1996;88(11):699–700. doi: 10.1093/jnci/88.11.699.
  21. Lu LY, Kuo JY, Lin TL, et al. Metastatic tumors involving the testis. J Urol ROC. 2000;11:12–6.
  22. Shaffer DW, Burris HA, O’Rourke TJ. Testicular Relapse in Adult Acute Myelogenous Leukemia. Cancer. 1992;70(6):1541–4. doi: 10.1002/1097-0142(19920915)70:6<1541::AID-CNCR2820700616>3.0.CO;2-6.
  23. Hanash KA. Metastatic tumors to the testicles. Prog Clin Biol Res. 1985;203:61–7.
  24. Ilieva IN, Toshkova RA, Sainova IV, et al. Histopathological Changes in the Testis of Hamsters with Experimentally Induced Myeloid Tumor of Graffi. Acta Morphol Anthropol. 2016;23:32–9.
  25. Ilieva IN, Toshkova RA, Zvetkova EB, et al. Morphological Studies on the Spermatogenesis and Graffi Myeloid Tumor Cell Dissemination (Metastases) in the Testes of Tumor-Bearing Hamsters. Acta Morphol Anthropol. 2017;24(1–2):33–40.
  26. Zvetkova EB, Toshkova RA. Photos of Monoblast from the Peripheral Blood of Graffi Myeloid Tumor-Bearing Hamster. In: BloodMed — Slide Athlas. Oxford; 2006.
  27. Ormandzhieva V, Toshkova RA. Мorphometrical Study of the Choroid Plexus Blood Vessels in Experimental Hamster Graffi Tumor Model. Acta Morphol Anthropol. 2015;22:31–6.
  28. Toshkova RA, Manolova N, Gardeva E, et al. Antitumor Activity of Quaternized Chitosan-based Electrospun Implants Against Graffi Myeloid Tumor. Int J Pharm. 2010;400(1–2):221–33. doi: 10.1016/j.ijpharm.2010.08.039.
  29. Toshkova RA, Krasteva IN, Nikolov SD. Immunorestoration and augmentation of mitogen lymphocyte response in Graffi tumor bearing hamsters by purified saponin mixture from Astragalus corniculatus. Phytomedicine. 2008;15(10):876–81. doi: 10.1016/j.phymed.2007.11.026.
  30. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of Vincristine in Combination with Methotrexate and Other Antitumor Agents in Human Acute Lymphoblastic Leukemia Cells in Culture. Cancer Res. 1988;48(2):351–6.
  31. Fukuda S, Shirahama T, Imazono Y, et al. Expression of Vascular Endothelial Growth Factor in Patients with Testicular Germ Cell Tumors as an Indicator of Metastatic Disease. Cancer. 1999;85(6):1323–30. doi: 10.1002/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15> .0.CO;2-G.
  32. Bart J, Groen HJ, van der Graaf WT, et al. An Oncological View on the Blood-testis Barrier. Lancet Oncol. 2002;3(6):357–63. doi: 10.1016/s1470-2045(02)00776-3.
  33. Dave DS, Leppert JT, Rajfer J. Is the Testis a Chemo-Privileged Site? Is There a Blood-Testis Barrier? Rev Urol. 2007;9(1):28–32.
  34. Yuceturk CN, Ozgur BC, Sarici H, et al. Testicular Involvement of Chronic Myeloid Leukemia 10 Years after the Complete Response. J Clin Diagn Res. 2014;8(4):ND03–ND04. doi: 10.7860/JCDR/2014/7847.4247.
  35. Hallak J, Mahran A, Chae J, Agarwal A. Poor semen quality from patients with malignancies does not rule out sperm banking. Urol Res. 2000;28(4):281–4. doi: 10.1007/s002400000129.
  36. Agarwal A, Allamaneni SSR. Disruption of Spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr. 2005;34:9–12. doi: 10.1093/jncimonographs/lgi005.
  37. Siu MKY, Cheng CY. The Blood-follicle Barrier (BFB) in Disease and in Ovarian Function. Adv Exp Med Biol. 2012;763:186–92. doi: 10.1007/978-1-4614-4711-5_9.
  38. Georgieva AK, Toshkova RA, Todorova KS, Tzoneva RD. Antineoplastic Effects of Erufosine on Graffi Myeloid Tumour in Hamsters. Bulg J Vet Med. 2021;24(3):442–9.
  39. Tekpli X, Holme JA, Sergent O, Lagadic-Gossmann D. Role for Membrane Remodelling in Cell Death: Implication for Health and Disease. Toxicology. 2013;304:141–57. doi: 10.1016/j.tox.2012.12.014.
  40. Wnetrzak A, Lipiec E, Latka E, et al. Affinity of Alkylphosphocholines to Biological Membrane of Prostate Cancer: Studies in Natural and Model Systems. J Membr Biol. 2014;247(7):581–9. doi: 10.1007/s00232-014-9674-8.
  41. Kostadinova A, Topouzova-Hristova T, Momchilova A, et al. Antitumor Lipids—Structure, Functions, and Medical Applications. In: R Donev, ed. Advances in Protein Chemistry and Structural Biology, Vol. 101. Burlington: Academic Press; 2015. pp. 27–66.
  42. Ignatov I, Drossinakis C, Toshkova RA, et al. Effects of Electromagnetic Fields over DNA in Tumor Diseases, Biophysical and Biochemical Model Systems. J Med Physiol Biophys. 2019:56:11–20.
  43. Toshkova RA, Zvetkova EB, Ignatov I, Gluhchev G. Effects of Catholyte Water on the Development of Experimental Graffi Tumor on Hamsters. Cell Cellular Life Sci J. 2019;4(1):1–9. doi: 10.23880/cclsj-16000140.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2023 Clinical Oncohematology